Prof. Dr. ÖMER DİZDAR

Yayın Ağı

Makaleler 197

1. Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment

Ozbay Y., ELDEM F. G., ÇAY F., BOZKURT M. F., Salanci B., Ormanci A., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , 2025 (SCI-Expanded, Scopus)

2. Incidence of Unexpected Lymph Node Positivity and Its Prognostic Impact in Patients Undergoing Pulmonary Metastasectomy

Kumbasar U., DİZDAR Ö., Uysal S., Yilmaz Y., Aydar I., KAŞIKCI ÇAVDAR M., et al.

INDIAN JOURNAL OF SURGERY , 2025 (SCI-Expanded, Scopus)

3. Adjuvant Gemcitabine-cisplatin Combination for Biliary Tract Cancer: A Real Life Experience

Kuş F., Yildirim H. c., Akyildiz A., Tatar O. D., Ozmen A., Sirvan F., et al.

Acta haematologica oncologica Turcica , cilt.58, sa.2, ss.121-126, 2025 (TRDizin)

4. Breast Radiotherapy: A Potential Risk Factor for Resistant Clone Development in Patients with Brain Metastasis

Yildirim H. c., Kavgacı G., Evlendi Y., CHALABIYEV E., Guven D. C., Dizdar O., et al.

Journal of oncological sciences , cilt.11, sa.1, ss.7-13, 2025 (TRDizin)

5. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center Experience

BAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.

JOURNAL OF CLINICAL MEDICINE , sa.8, 2025 (SCI-Expanded, Scopus)

6. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , sa.4, ss.129-137, 2025 (SCI-Expanded)

7. Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines

KUŞ F., Chalabiyev E., YILDIRIM H. Ç., Koc Kus I., ŞİRVAN F., DİZDAR Ö., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.35, sa.1, ss.68-74, 2025 (SCI-Expanded, Scopus, TRDizin)

8. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer

BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.

JOURNAL OF CLINICAL MEDICINE , sa.5, 2025 (SCI-Expanded, Scopus)

9. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Majidova N., Arak H., ÖZALP F. R., BAŞ O., ÖZÇELİK KÖKER G., Ozmarasali E. B., et al.

SCIENTIFIC REPORTS , sa.1, 2025 (SCI-Expanded, Scopus)

10. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , sa.1, ss.81-89, 2025 (SCI-Expanded)

11. PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy

Karahan L., HAYRAN K. M., DİZDAR Ö.

JAMA ONCOLOGY , sa.12, ss.1733, 2024 (SCI-Expanded, Scopus)

12. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., AKYILDIZ A., Ozcan E., et al.

JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus)

13. Cancer chemotherapy: incidence and predictors of 30-day mortality

DİZDAR Ö., DEMİR M., BOZBULUT U. B., HAYRAN K. M., Kars A.

BMJ SUPPORTIVE & PALLIATIVE CARE , sa.E2, 2024 (SCI-Expanded, Scopus)

14. Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report

Guener N. I., DİZDAR Ö., Tuerker A., EKİNCİOĞLU A.

ANTI-CANCER DRUGS , cilt.35, sa.9, ss.878-881, 2024 (SCI-Expanded, Scopus)

15. The effect of an empowerment program on ruminative thoughts, fatigue and psychological resilience of cancer survivors: A randomized controlled trial

Ocalan S., Uzar-Ozcetin S. Y., Dizdar O., Gurel C. S.

ANNALS OF ONCOLOGY , 2024 (SCI-Expanded, Scopus)

16. Sexual dysfunction and quality of life in rectal cancer

Kus F., Yildirim H. C., Guven D. C., Chalabiyev E., Sirvan F., Dizdar O., et al.

ANNALS OF ONCOLOGY , 2024 (SCI-Expanded, Scopus)

17. An Institutional Febrile Neutropenia Protocol Improved the Antibacterial Treatment and Encouraged the Development of a Computerized Clinical Decision Support System

TAŞ Z., METAN G., TELLİ DİZMAN G., Yavuz E., DİZDAR Ö., BÜYÜKAŞIK Y., et al.

ANTIBIOTICS-BASEL , cilt.13, sa.9, 2024 (SCI-Expanded, Scopus)

18. Predictors of early mortality after hemodialysis in patients with cancer and acute kidney injury

Gurbuz S. C., Kavgaci G., Sahin T. K., Kertmen N., Arici M., Dizdar O.

ANNALS OF ONCOLOGY , 2024 (SCI-Expanded, Scopus)

19. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.

SUPPORTIVE CARE IN CANCER , cilt.32, sa.7, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Acute heart failure following pazopanib treatment: a literature review featuring two case reports

KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.

Anti-Cancer Drugs , cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)

21. The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma

Sahin T., IŞIK A., Guven D., Ceylan F., BABAOĞLU B., AKYOL A., et al.

Pancreatology , cilt.24, sa.2, ss.279-288, 2024 (SCI-Expanded, Scopus)

22. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.

Vascular , 2024 (SCI-Expanded, Scopus)

23. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy

Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., et al.

International Journal of Clinical Oncology , 2024 (SCI-Expanded, Scopus)

24. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)

BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Öğüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., et al.

Internal and Emergency Medicine , 2024 (SCI-Expanded, Scopus)

25. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology

YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.

Irish Journal of Medical Science , cilt.192, sa.6, ss.2631-2634, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

26. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.

Medicine , cilt.102, sa.45, 2023 (SCI-Expanded, Scopus)

27. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.

Anti-cancer drugs , cilt.34, sa.10, ss.1190-1192, 2023 (SCI-Expanded, Scopus)

28. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.

Current Oncology , cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)

29. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.4, ss.170-176, 2023 (Scopus)

30. Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sample

Ozkan E., Ozcelikay G., Gök Topak E. D., NEMUTLU E., ÖZKAN S. A., DİZDAR Ö., et al.

Talanta , cilt.263, 2023 (SCI-Expanded, Scopus)

31. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Duran E., Ozturk Z. O., BİLGİN E., BÜYÜKAŞIK Y., DİZDAR Ö., Yardimci G. K., et al.

Rheumatology and Therapy , cilt.10, sa.4, ss.969-981, 2023 (SCI-Expanded, Scopus)

32. Advances in the Early Detection of Hepatobiliary Cancers

YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.

Cancers , cilt.15, sa.15, 2023 (SCI-Expanded, Scopus)

33. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

34. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)

35. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

Sütcüoğlu O., Doğan A., Yilmaz F., Şahin A. B., ŞAHİN T. K., Esen S. A., et al.

Pancreas , cilt.52, sa.4, 2023 (SCI-Expanded, Scopus)

36. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , cilt.47, sa.3, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

38. Smoker Relatives of Inpatients: A Reasonable but Heterogeneous Target Population for Smoking Cessation Program

AKTAŞ B. Y., HÜSEYİN B., YÜCE D., DİZDAR Ö., ERMAN M., HAYRAN M., et al.

Archives of Basic and Clinical Research , cilt.5, sa.1, ss.178-184, 2023 (TRDizin)

39. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)

40. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

42. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., et al.

SOUTH ASIAN JOURNAL OF CANCER , cilt.11, ss.287-292, 2022 (ESCI, Scopus)

44. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer

YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.9, 2022 (SCI-Expanded, Scopus)

45. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors

Sahin I., Saat H., AKSOY S., DİZDAR Ö., Erdem H. B., Bahsi T.

MOLECULAR AND CLINICAL ONCOLOGY , cilt.16, sa.1, 2022 (ESCI, Scopus)

48. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

49. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)

50. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment

Guven D. C., Taban H., Dizdar O.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.1, ss.203-204, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

51. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma

52. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

Guven D. C., Aktepe O. H., Aksun M. S., Sahin T. K., Kavgaci G., Ucgul E., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

53. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.12, ss.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

54. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.168, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

55. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)

56. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

57. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

59. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

Guven D. C., Yildirim H. C., Bilgin E., Aktepe O. H., Taban H., Sahin T. K., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY , cilt.23, sa.8, ss.1630-1636, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)

62. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data

Ozdemir N., DİZDAR Ö., YAZICI O., AKSOY S., Dede D. S., Budakoglu B., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.148, sa.10, ss.2407-2415, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

63. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus)

64. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

65. Comments on "Survival impact of adjuvant chemotherapy in patients with stageIIAcolon cancer: Analysis of the National Cancer Database"

DİZDAR Ö.

INTERNATIONAL JOURNAL OF CANCER , cilt.148, sa.4, ss.1027, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination

Sümbül A. T., YALÇIN S. S., ÖZET A., ÜNAL S., DİZDAR Ö., AKBULUT H., et al.

Journal of Oncological Science , cilt.7, sa.1, ss.1-6, 2021 (Scopus, TRDizin)

67. Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

Efil S. C., Guner G., Guven D. C., Celikten B., Celebiyev E., Taban H., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

68. What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis

Aktas B. Y., Degirmenciler R. F., Durmaz C. D., Taban H., Guven D. C., Guner G., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

69. Cancer incidence in Behcet's disease

GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.

IRISH JOURNAL OF MEDICAL SCIENCE , cilt.189, sa.4, ss.1209-1214, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

70. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives

C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S.

BIOMARKERS IN MEDICINE , cilt.14, ss.1383-1392, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

71. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past

Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.43, sa.9, ss.676, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

72. Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

73. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)

74. The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer

Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.2, ss.94-102, 2020 (SCI-Expanded, Scopus, TRDizin)

75. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

76. Classifying sarcopenia: using median value or cut-off values?

BAŞ O., DİZDAR Ö.

BREAST CANCER RESEARCH AND TREATMENT , cilt.176, sa.2, ss.479, 2019 (SCI-Expanded, Scopus)

77. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.19, sa.7, ss.589-601, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia

BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., et al.

Rheumatology International , cilt.39, sa.6, ss.1045-1051, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

79. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients

Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

BIOMARKERS IN MEDICINE , cilt.13, sa.9, ss.725-735, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

80. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded, Scopus)

81. The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy

ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., et al.

ANTI-CANCER DRUGS , cilt.30, sa.3, ss.289-294, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

82. Noninferiority for Short-HER or short-chemotherapy?

Aktas B. Y., Guven D. C., Dizdar O.

ANNALS OF ONCOLOGY , cilt.30, sa.1, ss.147, 2019 (SCI-Expanded, Scopus)

83. Evaluation of cancer risk in patients with periodontal diseases

Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.3, ss.826-831, 2019 (SCI-Expanded, Scopus, TRDizin)

84. Glucocorticoids in breast cancer treatment: real benefit or selection bias?

Guner G., DİZDAR Ö.

BREAST CANCER RESEARCH AND TREATMENT , cilt.172, sa.1, ss.243, 2018 (SCI-Expanded, Scopus)

85. When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis

Karakas Y., Vural S., DIKER O., DİZDAR Ö.

DERMATOLOGIC THERAPY , cilt.31, sa.6, 2018 (SCI-Expanded, Scopus)

86. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE

HAYRAN K. M., Yuce D., Kilickap S., Dizdar O., Huseyin B., Erman M., et al.

VALUE IN HEALTH , cilt.21, 2018 (SCI-Expanded, SSCI, Scopus)

87. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY AND RELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER

HAYRAN K. M., Yuce D., Kilickap S., Huseyin B., Erman M., Dizdar O., et al.

VALUE IN HEALTH , cilt.21, 2018 (SCI-Expanded, SSCI, Scopus)

88. The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival

KARAKAS Y., DİZDAR Ö., AKSOY S., Hayran M., Altundag K.

CLINICAL BREAST CANCER , cilt.18, sa.4, ss.320-327, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

89. Familial Mediterranean fever: new insights into cancer immunoprevention? Comment on the article by Brenner et al

BİLGİN E., Erden A., DİZDAR Ö.

ARTHRITIS & RHEUMATOLOGY , cilt.70, sa.7, ss.1167, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

90. Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey

ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.29, sa.4, ss.411-418, 2018 (SCI-Expanded, Scopus, TRDizin)

91. Factors associated with quitting action following smoking cessation counseling.

Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

92. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.

CURRENT PROBLEMS IN CANCER , cilt.42, sa.3, ss.344-349, 2018 (SCI-Expanded, Scopus)

93. Fusobacterium and colorectal carcinogenesis

Guven D. C., DİZDAR Ö.

CARCINOGENESIS , cilt.39, sa.1, ss.84, 2018 (SCI-Expanded, Scopus)

94. Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms

AKIN S., DİZDAR Ö., Hayran M.

ANNALS OF SURGICAL ONCOLOGY , cilt.24, 2017 (SCI-Expanded, Scopus)

95. Tumor Sidedness and Prognosis in Colorectal Cancer: Is Microbiome the Missing Link?

KARAKAS Y., DİZDAR Ö.

JAMA ONCOLOGY , cilt.3, sa.7, ss.1000, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

96. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database

DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.

JOURNAL OF BUON , cilt.22, sa.2, ss.530-534, 2017 (SCI-Expanded, Scopus)

97. Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience

Ates O., Aksoy S., Yeter H. H., Sunar V., Kertmen N., Dizdar O., et al.

INDIAN JOURNAL OF CANCER , cilt.54, sa.1, ss.321-325, 2017 (SCI-Expanded, Scopus)

98. Increased cancer risk in patients with periodontitis

DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., et al.

CURRENT MEDICAL RESEARCH AND OPINION , cilt.33, sa.12, ss.2195-2200, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

99. Vaccination perception and attitudes among patients with cancer receiving chemotherapy

AKIN Ş., DİZDAR Ö., Karakas Y., ÖZIŞIK L., Tanriover M. D., Kamisli S., et al.

ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded, Scopus)

100. Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes

Kucukoztas N., OĞUZ A., Rahatli S., Altundag O., Altundag K.

JOURNAL OF BUON , cilt.21, sa.5, ss.1076-1081, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

101. Interpretation of survival data: which graphical analysis is appropriate?

Dizdar O., AKIN S., HAYRAN M.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , cilt.8, sa.4, ss.312, 2016 (SCI-Expanded, Scopus)

102. Analysis of the Adjuvant Hormone Therapy Randomized Trial

Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.34, sa.17, ss.2070-2071, 2016 (SCI-Expanded, Scopus)

103. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy

AKIN S., DİZDAR Ö., ÖZIŞIK L., TANRIOVER M., KAMISLI S., ERMAN M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.167-172, 2016 (SCI-Expanded, Scopus, TRDizin)

104. Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer

Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E., OZGU E., TERZIOGLU S. G., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.2, ss.110-115, 2016 (SCI-Expanded, Scopus, TRDizin)

105. Advances in PARP inhibitors for the treatment of breast cancer

DİZDAR Ö., Arslan C., ALTUNDAG K.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.16, sa.18, ss.2751-2758, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

106. Is Dexamethasone a Better Partner for Abiraterone Than Prednisolone?

Dizdar O.

ONCOLOGIST , cilt.20, sa.5, 2015 (SCI-Expanded, Scopus)

107. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients

BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.50-56, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

108. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

Arslan C., Dizdar O., ALTUNDAG K.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.15, sa.12, ss.1643-1658, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

109. Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone

RAHATLI S., DİZDAR Ö., KÜÇÜKÖZTAŞ N., OĞUZ A., YALÇIN S., ÖZEN Ö., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.9, ss.3891-3893, 2014 (SCI-Expanded, Scopus)

110. Tertiary Cancer Center Experience: Pregnancy-Associated Breast Cancer

Kuzas T. Y., Koca E., BABACAN T., Turkbeyler I. H., Sarici F., Altundag K.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.24, sa.4, ss.284-285, 2014 (SCI-Expanded, Scopus, TRDizin)

111. Burnout syndrome during residency in internal medicine and pediatrics in a country without working time directive

YAZGAN AKSOY D., DURUSU TANRIÖVER M., ÜNAL S., DİZDAR Ö., KALYONCU U., KARAKAYA KARABULUT J., et al.

International Journal of Health Care Quality Assurance , 2014 (Scopus)

112. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , cilt.31, sa.8, ss.1709-1715, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

113. Outcomes of locally advanced breast cancer patients with >= 10 positive axillary lymph nodes

KOCA E., KUZAN T. Y., Dizdar O., Babacan T., SAHIN I., ARARAT E., et al.

MEDICAL ONCOLOGY , cilt.30, sa.3, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

114. Breast cancer in octogenarian women: clinical characteristics and outcome

Kuzan T. Y., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., et al.

JOURNAL OF BUON , cilt.18, sa.2, ss.328-334, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

115. Association of breast cancer subtypes and body mass index

Petekkaya I., ŞAHİN U., Gezgen G., Solak M., YÜCE D., DİZDAR Ö., et al.

TUMORI J , cilt.99, sa.2, ss.129-133, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

116. Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature

Koca E., Kuzan T. Y., BABACAN T., Turkbeyler I. H., Sarici F., Altundag K.

BREAST CARE , cilt.8, sa.6, ss.453-454, 2013 (SCI-Expanded, Scopus)

117. Frequency of thyroid disease among breast cancer patients: a descriptive study of breast cancer patients

Vural O., Dizdar O., Petekkaya I., Alnak A., Babacan T., Altundag K.

JOURNAL OF BUON , cilt.18, sa.1, ss.294-295, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

118. Impact of Treatment Strategies on Local Control and Survival in Uterine Carcinosarcomas in Turkey

Kucukoztas N., Dizdar O., Rahatli S., Dursun P., Yalcin S., Altundag O., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.5, ss.2959-2962, 2013 (SCI-Expanded, Scopus)

119. Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor

Kuria I. M., Petekkaya I., Hasanov E., Babacan T., Dizdar O., Altundag K.

JOURNAL OF BUON , cilt.17, sa.4, ss.798-799, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

120. Neuromyotonia forerunning the diagnosis of an eventual thymoma

Ozcakar L., Ozcan H. N., Dizdar O., Karaoglanoglu N., Tan E.

EUROPEAN JOURNAL OF NEUROLOGY , cilt.19, sa.9, 2012 (SCI-Expanded, Scopus)

121. Frequency of HCV infection in renal cell carcinoma patients

Budakoglu B., Aksoy S., ARSLAN Ç., Uyeturk U., Babacan N. A., Ozcan M. F., et al.

MEDICAL ONCOLOGY , cilt.29, sa.3, ss.1892-1895, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

122. Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., et al.

ONKOLOGIE , cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. Breast cancer subtypes and outcomes of central nervous system metastases

Arslan U. Y., Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., et al.

BREAST , cilt.20, sa.6, ss.562-567, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

124. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer

BULUT N., AKSOY S., DİZDAR Ö., Dede D. S., Arslan C., DOĞAN E., et al.

MEDICAL ONCOLOGY , cilt.28, 2011 (SCI-Expanded, Scopus)

125. Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature

Tapan U., DİZDAR Ö., Bulut N., ÇELİK İ.

EURASIAN JOURNAL OF MEDICINE , cilt.43, sa.3, ss.189-191, 2011 (ESCI, TRDizin)

126. Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response

ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., et al.

TUMORI , cilt.97, sa.6, ss.711-716, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

127. Vitamin D intake may be effective in the management of triple-negative breast cancer

Harputluoglu H., Dizdar O., Karaahmet F., Altundag K.

JOURNAL OF BUON , cilt.16, sa.3, ss.569, 2011 (SCI-Expanded, Scopus)

128. Pure mucinous carcinoma of the breast: a single center experience

Dogan E., Aksoy S., Dizdar O., Arslan C., Dede D. S., Ozisik Y., et al.

JOURNAL OF BUON , cilt.16, sa.3, ss.565-567, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

129. Frequency of HCV infection in renal cell carcinoma patients

Budakoglu B., Aksoy S., Arslan C., Uyeturk U., Babacan N. A., Ozcan M. F., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

130. Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report

DİZDAR Ö., YALÇIN Ş.

HEPATO-GASTROENTEROLOGY , cilt.58, sa.107, ss.859-860, 2011 (SCI-Expanded, Scopus)

131. Clinicopathologic features of patients with breast cancer under teatment of bisphosphonate at the time of diagnosis: Retrospective analysis

Dede D. S., Arslan C., Aksoy S., Dizdar O., Dogan E., Alkan A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

132. Clinical and pathological characteristics of very young breast cancer patients (<= 25 years of age)

Ararat E., Sahin I., Arslan C., Aksoy S., Dizdar O., Ozisik Y., et al.

JOURNAL OF BUON , cilt.16, sa.2, ss.372, 2011 (SCI-Expanded, Scopus)

133. Percentage of family history of cancer in patients with breast cancer: Is it changing with ethnicity?

Dizdar O., Arslan C., Altundag K.

JOURNAL OF BUON , cilt.16, sa.2, ss.373, 2011 (SCI-Expanded, Scopus)

134. Zoledronic acid and atrial fibrillation in cancer patients

ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S., HARPUTLUOĞLU H., ALTUNDAĞ M. K.

SUPPORTIVE CARE IN CANCER , cilt.19, sa.3, ss.425-430, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

135. Ipsilateral Breast Cancer in a Patient with Poland's Syndrome

Yesilkaya Y., DİZDAR Ö., Altundag K.

AMERICAN SURGEON , cilt.77, sa.2, ss.234-235, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

136. Malignancies after rituximab treatment: just coincidence or more?

Aksoy S., Arslan C., Harputluoglu H., Dizdar O., Altundag K.

JOURNAL OF BUON , cilt.16, sa.1, ss.112-115, 2011 (SCI-Expanded, Scopus)

137. Blood ABO groups and risk of breast cancer

ŞENER DEDE D., AKSOY S., DİZDAR Ö., Cerci P., Gullu İ. H., Ozisik Y., et al.

MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1433, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

138. Other malignancies in patients with breast cancer: a single institute experience

Dogan E., AKSOY S., DİZDAR Ö., ŞENER DEDE D., ARSLAN Ç., Ozisik Y., et al.

MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1434-1435, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

139. Two Important Determinants May Play a Role in the Success of the FinHer Trial

Isik M., DİZDAR Ö., Altundag K.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.20, 2010 (SCI-Expanded, Scopus)

140. Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates

AKSOY S., DİZDAR Ö., Altundag K.

MEDICAL ONCOLOGY , cilt.27, sa.2, ss.568, 2010 (SCI-Expanded, Scopus)

141. Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain

Dizdar O., Altundag M. K., Ozkok S., Ozsaran Z., Saip P., Eralp Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

142. Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?

Aksoy S., Arslan C., Kurt M., Dizdar O., Dede D. S., Dogan E., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus)

143. Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution.

Surmell Z. G., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

144. Systemic treatment in breast-cancer patients with brain metastasis

Arslan C., DİZDAR Ö., Altundag K.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.11, sa.7, ss.1089-1100, 2010 (SCI-Expanded, Scopus)

145. Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.

Ozen M., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

146. Clinical and pathological characteristics of breast cancer patients with history of tonsillectomy

Isik M., AKSOY S., Dede D. S., DİZDAR Ö., Kara A., Gullu İ. H., et al.

BREAST , cilt.19, sa.2, ss.152, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

147. Skin metastasis of ovarian cancer: a rare entity

Arslan C., Dede D. S., Dizdar O., Altundag K.

JOURNAL OF BUON , cilt.15, sa.2, ss.398-399, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

148. Synchronous Ovarian Cancer in a Patient with Pleomorphic Lobular Breast Cancer: A Therapeutic Dilemma

Dizdar O., Arslan C., Altundag K.

CLINICAL ONCOLOGY , cilt.22, sa.2, ss.153-154, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

149. Clinical and pathological characteristics of breast cancer patients with history of cesarean delivery

Kalan I., Turgut D., AKSOY S., ŞENER DEDE D., DİZDAR Ö., Ozisik Y., et al.

BREAST , cilt.19, sa.1, ss.67-68, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

150. Current and emerging treatment options in triple-negative breast cancer

DİZDAR Ö., Altundag K.

ONCOLOGY REVIEWS , cilt.4, sa.1, ss.5-13, 2010 (ESCI, Scopus) Sürdürülebilir Kalkınma

151. Estrogen receptor immunohistochemistry cutoff value: Standardization is needed

ARSLAN Ç., DİZDAR Ö., Altundag K.

HUMAN PATHOLOGY , cilt.41, sa.1, ss.150, 2010 (SCI-Expanded, Scopus)

152. Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia

DİZDAR Ö., Oezcakar L., Malas F. U., HARPUTLUOĞLU H., Bulut N., Aksoy S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.30, ss.4955-4960, 2009 (SCI-Expanded, Scopus)

153. Chemotherapy in Older Women with Breast Cancer

DİZDAR Ö., ŞENER DEDE D., Altundag K.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.361, sa.10, ss.1023, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

154. Pharmacotherapy of triple-negative breast cancer

ARSLAN Ç., DİZDAR Ö., Altundag K.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.10, sa.13, ss.2081-2093, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

155. Pathological characteristics of very young (<= 30 years) breast cancer patients: a single-institution experience from Turkey

Aksoy S., Bulut N., Dizdar O., Tosur M., Meral A., Altundag K.

ANNALS OF ONCOLOGY , cilt.20, sa.4, ss.790, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

156. Reproductive and Hormonal Risk Factors for Postmenopausal Luminal, HER-2-overexpressing, and Triple-negative Breast Cancer

DİZDAR Ö., AKSOY S., Altundag K.

CANCER , cilt.115, sa.8, ss.1802, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

157. Emerging drugs in metastatic breast cancer

DİZDAR Ö., Altundag K.

EXPERT OPINION ON EMERGING DRUGS , cilt.14, sa.1, ss.85-98, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

158. Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation

KALYONCU U., DİZDAR Ö., Duman A. E., KARADAĞ Ö., TUFAN A., Yucel O., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.15, sa.1, ss.103-108, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

159. Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?

Dizdar O., Aksoy S., Altundag K.

ANNALS OF ONCOLOGY , cilt.20, sa.1, ss.189, 2009 (SCI-Expanded, Scopus)

160. Prognostic factors in long-term breast cancer survivors with brain metastases

Harputluoglu H., Kara A., DİZDAR Ö., Surmeli Z. G., Altundag K.

BREAST CANCER RESEARCH AND TREATMENT , cilt.112, sa.1, ss.215, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

161. Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment

AKSOY S., DİZDAR Ö., Altundag K.

BREAST , cilt.17, sa.5, ss.433-435, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

162. Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors

Harputluoglu H., DİZDAR Ö., Karaahmet F., Altundag K.

BREAST CANCER RESEARCH AND TREATMENT , cilt.110, sa.3, ss.541, 2008 (SCI-Expanded, Scopus)

163. Weekly paclitaxel in the adjuvant treatment of breast cancer

AKSOY S., DİZDAR Ö., Altundag K.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.359, sa.3, ss.310, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

164. A case report: zoledronic acid-induced anterior uveitis

KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K., DİZDAR Ö.

MEDICAL ONCOLOGY , cilt.25, sa.2, ss.238-240, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

165. Aromatase inhibitor-associated arthralgia: Prevalence, clinical and serum parameters among Turkish postmenopausal breast cancer patients

Harputluoglu H., Dizdar O., Malas F. U., Ozcakar L., Bulut N., Ozisik Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

166. Prognostic impact of bone turnover markers in multiple myeloma

Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus)

167. Clinicopathologic evaluation of non-Hodgkin lymphoma (NHL): A single centre experience

Kilickap S., Barista I., Turkmen E., Dizdar O., Aksoy S., Turker A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus)

168. Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer

DİZDAR Ö., Bulut N., Altundag K.

BREAST CANCER RESEARCH AND TREATMENT , cilt.109, sa.2, ss.403, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

169. Characteristics of breast cancer patients with central nervous system metastases: A single-center experience

Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S., Ozisik Y., et al.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION , cilt.100, sa.5, ss.521-526, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

170. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C

DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.

EUROPEAN JOURNAL OF HAEMATOLOGY , cilt.80, sa.5, ss.381-385, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

171. Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer

DİZDAR Ö., Bulut N., Altundag K.

BREAST , cilt.17, sa.2, ss.120, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

172. Prognostic factors in breast cancer patients with brain metastases

Harputluoglu H., DİZDAR Ö., Altundag K.

JOURNAL OF NEURO-ONCOLOGY , cilt.87, sa.2, ss.193, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

173. Efficacy of chemotherapy for brain metastases from breast carcinoma: In regard to Le Scodan et al. (Int J Radia T Oncol Biol Phys 2007;69 : 839-845)

DİZDAR Ö., Tapan U., Altundag K.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.70, sa.5, ss.1615, 2008 (SCI-Expanded, Scopus)

174. Erectile dysfunction in successfully treated lymphoma patients

AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al.

SUPPORTIVE CARE IN CANCER , cilt.16, sa.3, ss.291-297, 2008 (SCI-Expanded, Scopus)

175. Familial chemosensitivity test: Can it be a predictive factor in the management of familial breast cancer?

DİZDAR Ö., Harputluoglu H., Altundag K.

BREAST , cilt.17, sa.1, ss.5, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

176. Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines

DİZDAR Ö., ŞENER DEDE D., Bulut N., Altundag K.

BREAST CANCER RESEARCH AND TREATMENT , cilt.107, sa.2, ss.303, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

177. Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer

Bulut N., Harputluoglu H., Dizdar O., Altundag K.

JOURNAL OF NEURO-ONCOLOGY , cilt.86, sa.2, ss.241, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

178. Potential targeted therapy options in the management of basal cell subtype of breast carcinoma

Harputluoglu H., DİZDAR Ö., Altundag K.

HUMAN PATHOLOGY , cilt.38, sa.12, ss.1869, 2007 (SCI-Expanded, Scopus)

179. Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer

DİZDAR Ö., Harputluoglu H., Altundag K.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.69, sa.5, ss.1651, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

180. Vitamin D intake and breast cancer risk in postmenopausal women

Dizdar O., Harputluoglu H., Altundag K.

ARCHIVES OF INTERNAL MEDICINE , cilt.167, sa.22, ss.2532, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

181. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience

Aksoy S., Dizdar O., Harputluoglu H., Altundag K.

ANNALS OF ONCOLOGY , cilt.18, sa.11, ss.1904-1906, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

182. Bone mineral density in breast cancer patients with estrogen receptor-negative tumor

Dede D. S., Dizdar O., Harputluoglu H., Altundag K.

MATURITAS , cilt.58, sa.3, ss.324, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

183. Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital

Dizdar O., Karadag O., Kalyoncu U., Kurt M., ULGER Z., SARDAN Y. C., et al.

JOURNAL OF EVALUATION IN CLINICAL PRACTICE , cilt.13, sa.3, ss.408-411, 2007 (SCI-Expanded, Scopus)

184. Rituximab-induced viral infections in lymphoma patients

Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus)

185. Predictive factors for metastasis in patients (pts) with gastric cancer

Kilickap S., Dizdar O., Harputluoglu H., Aksoy S., YALÇIN S. S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

186. Research for bleeding tendency in patients presenting with significant epistaxis

Dizdar O., Onal I. K., Ozakin E., Karakilic E., Karadag O., Kalyoncu U., et al.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.18, sa.1, ss.41-43, 2007 (SCI-Expanded, Scopus)

187. Macrophage inflammatory protein-1 alpha: A link between innate immunity and familial mediterranean fever?

Dizdar O., Kalyoncu U., Karadag O., Akdogan A., Kiraz S., Ertenli I., et al.

CYTOKINE , cilt.37, sa.1, ss.92-95, 2007 (SCI-Expanded, Scopus)

188. Rituximab-related viral infections in lymphoma patients

Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., et al.

LEUKEMIA & LYMPHOMA , cilt.48, sa.7, ss.1307-1312, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

189. Mucosa associated lymphoid tissue lymphoma of the sub mandibular gland presenting with relapse in the lacrimal gland

KURT M., Shorbagi A., ALTUNDAĞ M. K., AKYÖN YILMAZ Y., DİZDAR Ö., GÜLLÜ İ. H.

Leukemia , cilt.47, ss.1982-1984, 2006 (SCI-Expanded)

190. Coincidence of increased pulmonary artery pressure and patent septum foramen ovate in patients with solid tumors may have a propensity to develop central nervous system metastases

Harputluoglu H., Dizdar O., Altundag K.

MEDICAL HYPOTHESES , cilt.67, sa.4, ss.996, 2006 (SCI-Expanded, Scopus)

191. Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma

Abali H., Eren O., Dizdar O., Karadag O., Erman M., Yilmaz A., et al.

LEUKEMIA & LYMPHOMA , cilt.46, sa.12, ss.1825-1828, 2005 (SCI-Expanded, Scopus)

192. Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity

Onal I., Ozcakar L., Dizdar O., Buyukasik Y., Dundar S.

RHEUMATOLOGY INTERNATIONAL , cilt.25, sa.7, ss.569-570, 2005 (SCI-Expanded, Scopus)

193. Orbital metastasis from adenocarcinoma of the colon

Dizdar O., Aksoy S., Kilickap S., Yalcin S.

SOUTHERN MEDICAL JOURNAL , cilt.98, sa.8, ss.846-847, 2005 (SCI-Expanded, Scopus)

194. Group B streptococcal facet joint arthritis - Case report

Dizdar O., Alyamac E., Onal I., Uzun O.

SPINE , cilt.30, sa.14, 2005 (SCI-Expanded, Scopus)

195. Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia

Dizdar O., Yurekli B., Purnak T., Aksu S., Haznedaroglu I.

ANNALS OF PHARMACOTHERAPY , cilt.38, ss.1319-1320, 2004 (SCI-Expanded, Scopus)

196. Membranoproliferative glomerulonephritis associated with type 1 diabetes mellitus and Hashimoto's thyroiditis

Dizdar O., Kahraman S., Genctoy G., Ertoy D., Arici M., Altun B., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.19, sa.4, ss.988-989, 2004 (SCI-Expanded, Scopus)

197. Obesity: an endocrine tumor?

Dizdar O., Alyamac E.

MEDICAL HYPOTHESES , cilt.63, sa.5, ss.790-792, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 50

1. Incidence of unexpected lymph node positivity and its prognostic impact in patients undergoing pulmonary metastasectomy

KUMBASAR U., DİZDAR Ö., UYSAL S., DİKMEN E., YALÇIN Ş.

14th International Gastrointestinal Cancer Conference, İstanbul, Türkiye, 28 Kasım 2024, (Özet Bildiri)

2. Comprehensive approach focusing on the molecular profile of a rare genodermatosis: Epidermodysplasia Verruciformis

ERKAN D. D., Akcin O., DURMAZ ÖZDİNÇ C. D., ATEŞ ÖZDEMİR D., GÜLERAY LAFCI N., DİZDAR Ö.

56th Annual Conference of the European-Society-of-Human-Genetics (ESHG), Glasgow, İngiltere, 10 - 13 Haziran 2023, ss.397, (Özet Bildiri)

3. Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer

Bas O., Erdemir A., Onur R., Guner G., Guven D. C., Aksu S., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

4. Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days

Aktas B. Y., Guven D. C., Degirmenciler R. F., Taban H., Aktepe O. H., Kertmen N., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

5. Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic

Guven D. C., Ceylan F., Cakir I. Y., Cesmeci E., Sayinalp B., Yesilyurt B., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

6. Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients

Guven D. C., Aktas B. Y., Aksun M. S., Ucgul E., Sahin T. K., Yildirim H. C., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

7. Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., Kilickap S., Turker A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

8. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)

9. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

10. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

11. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?

BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.

Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.993, (Özet Bildiri)

12. Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.

Aktas B. Y., Kayku V. E., Aslan A., Kertmen N., Dizdar Ö., Yalcin S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) Sürdürülebilir Kalkınma

13. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

14. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER

HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, cilt.1, ss.11, (Tam Metin Bildiri)

15. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE

HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

16. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi

GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.

2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

17. Compliance to the guideline of diagnostic tests in febrile neutropenic patients at a Turkish university hospital’

ZARAKOLU KÖŞKER I. P., AKOVA M., BÜYÜKAŞIK Y., DURUSU TANRIÖVER M., DİZDAR Ö., METAN G., et al.

20th Symposium on Infections in the immunocompromised host, Atina, Yunanistan, 17 - 19 Haziran 2018, (Tam Metin Bildiri)

18. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”

GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.

2018 ASCO, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, (Özet Bildiri)

19. Evaluation of cancer risk in patients with periodontal diseases.

GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.

2018 ASCO Annual Meeting, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, cilt.36, ss.13571, (Özet Bildiri)

20. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi

GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

21. Multimodality treatment in malignant peripheral nerve sheath tumors

KARAKAŞ Y., DİZDAR Ö., KÖSEMEHMETOĞLU K., GEDİKOĞLU M. G., SÖYLEMEZOĞLU A. F., BOZBULUT U. B., et al.

International Congress on oncological sciences, 28 Eylül - 01 Ekim 2017, (Özet Bildiri)

22. Using Taylor Regression to Identify Points of Cahnge in Local Cancer Trends

HAYRAN K. M., YÜCE D., DİZDAR Ö.

GAP 2017 CONFERENCE, 9 - 11 Mayıs 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

23. SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK

DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., et al.

GAP 2017 Conference, Texas, Amerika Birleşik Devletleri, 9 - 11 Mayıs 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

24. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program

AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.

7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

25. Evaluating Admissions of Foreign Patients to a University Hospital in Turkey

HAYRAN K. M., YÜCE D., DENEK S., DİZDAR Ö.

International Forum for Quality Cancer Care, 27 - 29 Ekim 2016, (Tam Metin Bildiri)

26. Using geographical information systems to describe quality of life as a function of distance in cancer patients

HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.

ISPOR Asia Pacific Meeting 2016, 3 - 06 Eylül 2016, cilt.19, ss.892, (Özet Bildiri)

27. The impact of the total size of lesions in multifocal multicentric breast cancer on survival

Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

28. Intravenous ferric carboxymaltose treatment in cancer patients

ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

29. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma

ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)

30. Pleomorphic lobular carcinoma of the breast associated with impaired overall survival

Hacioglu M. B., Babacan T., Diker O., Akin S., Demir M., Dizdar O., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

31. Neuroendocrine breast cancer A single center experience

TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.

2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

32. Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.

Arik Z., Dizdar O., Yildirim M. E., Ozgu E., Oz M., Terzioglu S. G., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

33. Correlation of histopahologic response and prognostic markers with survival in locally advanced non-small cell lung cancer patients who have treated with neoadjuvant chemotherapy.

Kucukoztas N., Oguz A., Rahatli S., Dizdar O., Keskin G. S. Y., Ozyilkan O., et al.

34. Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.

35. Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.

Oguz A., Babacan T., Dizdar O., Kucukoztas N., Rahatli S., Keskin G. S. Y., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

36. Is there any correlation between molecular subtypes and blood groups in breast cancer?

Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

37. Outcomes of patients with endometrial cancer and aggressive histology.

Rahatli S., Kucukoztas N., Dizdar O., Dursun P., Yalcin S., Haberal N., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

38. Impact of treatment strategies on local control and survival in uterine carcinosarcomas.

Yalcin S., Dizdar O., Kucukoztas N., Rahatli S., Ozen O., Dursun P., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

39. Impact of comorbidities on recurrence rates and survival in patients with endometrial cancer.

Kucukoztas N., Dizdar O., Rahatli S., Tarhan C., Haberal N., Dursun P., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

40. Retrospective analysis of stage IIIc uterine carcinoma patients: A single center experience.

Yalcin S., Rahatli S., Kucukoztas N., Ozen O., Haberal N., Tarhan C., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)

41. Outcome of breast cancer patients with stage I diesease: A retrospective analysis

Ergun A., Kucukoztas N., Yalcin S., Rahatli S., Babacan T., Yagmurdur M. C., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

42. Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.

Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

43. Retrospective analysis of stage IC uterine cancer patients: A single center experience.

Kucukoztas N., Yalcin S., Rahatli S., Ozen O., Haberal N., Tarhan C., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

44. The Frequency and Determinants of Metabolic Syndrome in Patients with Operable Stage I-III Breast Cancer.

Aksoy S., Dizdar O., Dede D. S., Arslan C., Dogan E., Tapan U., et al.

32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 13 Aralık 2009, cilt.69, (Özet Bildiri) Sürdürülebilir Kalkınma

45. Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis

Dede D. S., Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., et al.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri) Sürdürülebilir Kalkınma

46. Zoledronic acid and atrial fibrillation in cancer patients with bone metastases

Aksoy S., Dizdar O., Turgut D., Dede D. S., Arslan C., Harputluoglu H., et al.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri) Sürdürülebilir Kalkınma

47. Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis

Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S., Ozisik Y., et al.

30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 13 - 16 Aralık 2007, cilt.106, (Özet Bildiri) Sürdürülebilir Kalkınma